Hammersmith Medicines Research

HMR London

Facilities and services

We specialise in early clinical trials of study drugs for pharmaceutical and biotechnology companies worldwide.
Founded in 1993, HMR is now the biggest CRO of its kind in the UK and one of the biggest in Europe.
We have 270 staff, including a resident 24/7 resuscitation team, extensive purpose-built facilities, 145 beds, and on-site pharmacy, radiopharmacy, and laboratory.
We can provide a full service from design to clinical study report, all in one building in London, UK.
Our level of service and commitment is the same for all companies, regardless of size.
HMR has: MHRA Phase 1 Accreditation for FIH trials; Manufacturing and Import Licence for study drugs [MIA(IMP)]; Home Office licence for all controlled drug substances; and Environment Agency licence for trials of radiolabelled study drugs.
Our Quality System is compliant with ISO 9001, our Laboratory with ISO 17025, and our Information Security Management System with ISO 27001.
We’ve won three Queen’s Awards for Exports or Enterprise, the most prestigious of UK business awards.

We have completed >900 trials for pharmaceutical and biotechnology companies from 23 countries worldwide, including all 15 major companies by revenue, and >200 small-to-medium sized or virtual companies.
We can do almost all types of trial, from simple bioequivalent to complex trials, such as endoscopy, sleep, radiopharmacy, bridging, QTc, and PET, fMRI or CT imaging.
Many of our trials are first-in-human (FIH) and proof-of-concept in design and range from small to large and complex trials with adaptive protocol and several parts.
Most of the study drugs are small molecules, but we also do many trials of biological products, such as recombinant proteins, monoclonal antibodies, vaccines, and small interfering RNA molecules.
Most of our trials are in healthy subjects, but many include patients with the target disease; some trials involve only patients.
We have a large database of healthy subjects of all ages and ethnicities, and many types of patient.
We collaborate with London universities, hospitals, and general practices for trials requiring patients.

We don’t have a business development team. We rely solely on reputation, recommendations, record, and repeat business, a unique testament to the quality of our services.
The UK is a good place to do clinical trials: the regulatory system is rigorous, efficient, and supportive of clinical pharmacology and sponsors and can help sponsors to plan their FIH trials.
The MHRA and FDA inspectors have never reported any important GCP or GMP findings.
Our pharmacy prepares and QP releases all types of dose. Our laboratory provides rapid turnaround of safety samples, and a wide range of biomarkers, such as flow cytometry, cytokine, coagulation, platelet aggregation, and PCR tests.
We developed TOPS, a database to register participants in UK phase 1 trials; use is now mandatory for regulatory approval of phase 1 trials.
We PCR test all subjects for SARS-Cov-2, and admit only negative subjects. We PCR test all front-line staff regularly. So far we’ve kept the virus out of our trials.
Together with sponsors, we publish results of our trials in peer-reviewed journals.